Asset profile
Oxylanthanum carbonate
Small molecule
Evidence outlook · lead readout
NCT06218290 · Chronic Kidney Disease Requiring Chronic Dialysis
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT06218290: The study treated 106 participants in a single open-label group without randomization or a comparator arm. Its primary endpoint was the incidence of treatment-related adverse events leading to discontinuation, but no primary results were posted, so whether the endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.